Video

June 29, 2022

Dr. Rovner on adherence to AUA publication guidelines for SUI literature

Author(s):

Eric S. Rovner, MD, professor of Urology, Medical University of South Carolina (MUSC), discusses the abstract, “Revisiting adherence to the AUA publication guidelines for SUI literature,” which was presented at the 2022 AUA Annual Meeting.

Related Content

March 14th 2025

Trial launches of gene therapy vector for neurogenic bladder due to spinal cord injury

Hannah Clarke

The 52-week study plans to enroll 16 patients across 4 sites in the US.

$Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB$

March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

February 28th 2025

Pivotal study data show efficacy of percutaneous SNM device for UUI

Hannah Clarke

Overall, 84.2% of patients achieved a 50% or greater reduction in urgent leaks.

March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

February 7th 2025

Published OASIS data show durable efficacy of Revi System for UUI

Hannah Clarke

At 24 months, 79% of patients experienced a response to therapy, and 56% achieved at least a 75% reduction in UUI episodes.

January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke

Functional success was achieved in 58% of patients at 5-year follow-up.

Related Content

March 14th 2025

Trial launches of gene therapy vector for neurogenic bladder due to spinal cord injury

Hannah Clarke

The 52-week study plans to enroll 16 patients across 4 sites in the US.

$Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB$

March 21st 2022

Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB

Urology Times staff

“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.

February 28th 2025

Pivotal study data show efficacy of percutaneous SNM device for UUI

Hannah Clarke

Overall, 84.2% of patients achieved a 50% or greater reduction in urgent leaks.

March 18th 2022

Destigmatizing Urology: Dr. Alexandra Rogers discusses OAB

Urology Times staff

“We need to improve the fact that 75% of these patients are untreated [or] unmanaged and frustrated,” says Alexandra Rogers, MD.

February 7th 2025

Published OASIS data show durable efficacy of Revi System for UUI

Hannah Clarke

At 24 months, 79% of patients experienced a response to therapy, and 56% achieved at least a 75% reduction in UUI episodes.

January 20th 2025

ROBUST I: Optilume maintains durable efficacy, safety for urethral strictures

Hannah Clarke

Functional success was achieved in 58% of patients at 5-year follow-up.